Royalty Pharma PLC (NASDAQ:RPRX) Given Average Rating of "Buy" by Analysts

Key Points

• Royalty Pharma PLC has received an average analysts' rating of "Buy", with one hold rating, three buy ratings, and one strong buy rating.
• The average 12-month price target among analysts for Royalty Pharma is $46.00, while recent updates from Morgan Stanley and Citigroup have adjusted their price targets to $54.00 and $42.00, respectively.
• Royalty Pharma recently announced a quarterly dividend of $0.22 per share, which translates to an annualized dividend of $0.88 and a yield of 2.4%.

Shares of Royalty Pharma PLC (NASDAQ:RPRX - Get Free Report) have been given an average recommendation of "Buy" by the five brokerages that are currently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $46.00.

A number of equities research analysts have recently weighed in on RPRX shares. Morgan Stanley lifted their price target on shares of Royalty Pharma from $51.00 to $54.00 and gave the company an "overweight" rating in a research report on Thursday, July 10th. Wall Street Zen cut shares of Royalty Pharma from a "buy" rating to a "hold" rating in a research note on Saturday, September 13th. Citigroup lifted their price objective on shares of Royalty Pharma from $40.00 to $42.00 and gave the company a "buy" rating in a research note on Tuesday, July 22nd. The Goldman Sachs Group began coverage on shares of Royalty Pharma in a research note on Tuesday. They issued a "buy" rating and a $42.00 price objective on the stock. Finally, Weiss Ratings reissued a "hold (c+)" rating on shares of Royalty Pharma in a research note on Saturday, September 27th.

Institutional Trading of Royalty Pharma

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Aaron Wealth Advisors LLC bought a new stake in shares of Royalty Pharma during the third quarter worth $436,000. GAMMA Investing LLC lifted its holdings in Royalty Pharma by 9.6% in the third quarter. GAMMA Investing LLC now owns 3,306 shares of the biopharmaceutical company's stock valued at $117,000 after buying an additional 289 shares during the period. Osaic Holdings Inc. lifted its holdings in Royalty Pharma by 134.8% in the second quarter. Osaic Holdings Inc. now owns 7,104 shares of the biopharmaceutical company's stock valued at $254,000 after buying an additional 4,078 shares during the period. Orion Porfolio Solutions LLC lifted its holdings in Royalty Pharma by 56.9% in the second quarter. Orion Porfolio Solutions LLC now owns 14,420 shares of the biopharmaceutical company's stock valued at $520,000 after buying an additional 5,231 shares during the period. Finally, Squarepoint Ops LLC acquired a new position in Royalty Pharma in the second quarter valued at $9,848,000. Institutional investors own 54.35% of the company's stock.

Royalty Pharma Price Performance

Shares of NASDAQ RPRX traded down $0.42 during midday trading on Friday, reaching $36.07. The company's stock had a trading volume of 2,207,344 shares, compared to its average volume of 6,037,434. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.26 and a current ratio of 1.26. Royalty Pharma has a fifty-two week low of $24.05 and a fifty-two week high of $38.00. The business's 50 day moving average price is $36.28 and its two-hundred day moving average price is $34.55. The company has a market cap of $21.03 billion, a P/E ratio of 20.85, a P/E/G ratio of 2.28 and a beta of 0.60.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The biopharmaceutical company reported $1.14 earnings per share for the quarter, beating analysts' consensus estimates of $1.10 by $0.04. Royalty Pharma had a net margin of 44.23% and a return on equity of 25.54%. The company had revenue of $578.67 million during the quarter, compared to the consensus estimate of $750.06 million. On average, analysts forecast that Royalty Pharma will post 4.49 EPS for the current fiscal year.

Royalty Pharma Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Wednesday, September 10th. Shareholders of record on Friday, August 15th were paid a dividend of $0.22 per share. This represents a $0.88 dividend on an annualized basis and a dividend yield of 2.4%. The ex-dividend date of this dividend was Friday, August 15th. Royalty Pharma's payout ratio is presently 50.87%.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.